Execs On The Move, September 2014
Executive Summary
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
You may also be interested in...
Celltrion Makes Tocilizumab Progress With Positive Data At EULAR 2023
At the European Society of Rheumatology conference currently taking place in Milan, Italy, Celltrion unveiled progress for its proposed biosimilar to Roche’s Actemra/RoActemra (tocilizumab).
US Drug Shortages Aid Aurobindo’s Q4 Growth, Decentralized Trials On For Xolair Biosimilar
Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair, as predicted by Scrip earlier. Use of decentralized mode for its Phase III trials is a notable aspect
Samsung Bioepis Quiet On Launch Date After EU Soliris Biosimilar Approval
Samsung Bioepis responded to Generics Bulletin enquiries following its EU-wide approval for a biosimilar to AstraZeneca’s Soliris.